Clinical trial NCT06369519: Optimization of Management for Sporadic Bilateral Renal Cell Carcinoma
Official title: Optimization of Management for Sporadic Bilateral Renal Cell Carcinoma: a Population-based Cohort Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Kidney Cancer
Keywords: Bilateral renal cell carcinoma
Surgery
Partial nephrectomy
Local tumor destruction
Nomogram
Lead sponsor: Peking University First Hospital
Sponsor class: OTHER
First posted: 2024-04-17
Enrollment: 3677
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This study was based on the Surveillance, Epidemiology, and End Results (SEER) database, which contains the population-based data from 17 Registries covering approximately 26.5% of the U.S. population. The eligible sporadic localized BRCC patients were identified from the SEER database.

Brief summary: Sporadic bilateral renal cell carcinoma (BRCC) is a rare situation of RCC. The treatment for BRCC is controversial and there is a lack of authoritative guidelines about the management of BRCC. The goal of this cohort study is to identify prognostic factors, construct predictive nomograms, and optimize management for sporadic BRCC patients. The main questions it aims to answer are:

What are the factors influencing the prognosis of BRCC patients? What's the appropriate treatment for BRCC patients?

Researchers will analysis the prognostic factors and compare the prognosis of BRCC patients receiving different treatments.

Detailed description: Sporadic bilateral renal cell carcinoma (BRCC) is a rare situation of RCC. The treatment for BRCC is controversial and there is a lack of authoritative guidelines about the management of BRCC. This cohort study aims to identify prognostic factors, construct predictive nomograms, and optimize surgical treatment for sporadic BRCC patients. The main questions it aims to answer are:

What are the factors influencing the prognosis of BRCC patients? What's the appropriate treatment for BRCC patients? In this retrospective population-based cohort study, patients diagnosed with sporadic BRCC between 2000 and 2020 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Researchers will analysis the prognostic factors and compare the prognosis of BRCC patients receiving different treatments.

Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years.
* Clinical diagnosis of localized BRCC (M0) from 2000 to 2020.
* Active follow-up.
* Complete clinicopathological information.

Exclusion Criteria:

* Diagnosed by autopsy or death certificate only.
* Tending to suffer from hereditary RCC, including those complicating with pancreatic neuroendocrine tumor (pNET) or hemangioblastoma.
* Unavailable key information.

Primary outcomes:
measure: Overall survival (OS)
timeFrame: From date of diagnosis of the second primary RCC until the date of death from any cause or the date of last follow-up, whichever came first, assessed up to 20 years.
Secondary outcomes:
measure: Cancer-specific survival (CSS)
timeFrame: From date of diagnosis of the second primary RCC until the date of death from the same disease or the date of last follow-up, whichever came first, assessed up to 20 years.
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking University First Hospital
state: Beijing
Study officials:
affiliation: Peking University First Hospital
name: Kan Gong
role: PRINCIPAL_INVESTIGATOR
References: